WEIGHT MANAGEMENT
AOD-9604
Also known as Anti-Obesity Drug 9604, hGH Fragment 176-191
AOD-9604 is a synthetic hGH fragment developed for metabolic research. Obesity trials did not show enough clinical efficacy to support drug approval. US GRAS status relates to use as a food ingredient and does not validate injectable use.
Reference dose range
300–1000 mcg
Reported frequency
Two to three times daily in research references
Reported routes
Subcutaneous
Very short half-life; frequency references come from research settings.
Use the calculators for arithmetic only
Mechanism
AOD-9604 is a modified fragment of human growth hormone corresponding to the 176-191 region. It was developed to explore metabolic signals associated with lipolysis without reproducing the full effect profile of hGH. Clinical relevance remains limited by trial results.
Reported effects
Fat-oxidation signals in preclinical studies
Lipogenesis inhibition described in early research
Limited tolerability data in human studies
Commonly reported side effects
Administration-site reactions
Certainty and limits
Efficacy for obesity was not confirmed in advanced clinical development. Wellness-use reports are not validated by clinical trials. GRAS status should not be interpreted as therapeutic approval.
This is part of the reviewed public subset. The signed-in app includes a broader peptide reference library alongside private tracking tools.